{"filing":{"accession_number":"0001193125-26-279776","cik":"0001369568","ticker":"CPRX","company_name":"CATALYST PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"d166178d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526279776/d166178d8k.htm"},"events":[{"id":13280,"run_id":11787,"accession_number":"0001193125-26-279776","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"This Item 8.01 discloses a material acquisition event: Catalyst Pharmaceuticals entered into a Merger Agreement with Angelini Pharma on May 6, 2026, providing for the merger of Angelini's subsidiary with Catalyst, with Catalyst surviving as a wholly-owned subsidiary of Angelini Pharma. The filing updates that the FTC granted early termination of the HSR Act waiting period on June 16, 2026, and the parties expect closing in Q3 2026 subject to customary conditions including stockholder approval. This is a change-of-control transaction material to any reasonable investor.","company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10381,"accession_number":"0001193125-26-279776","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This Item 8.01 discloses a material acquisition event: Catalyst Pharmaceuticals entered into a Merger Agreement with Angelini Pharma on May 6, 2026, providing for the merger of Angelini's subsidiary with Catalyst, with Catalyst surviving as a wholly-owned subsidiary of Angelini Pharma. The filing updates that the FTC granted early termination of the HSR Act waiting period on June 16, 2026, and the parties expect closing in Q3 2026 subject to customary conditions including stockholder approval. This is a change-of-control transaction material to any reasonable investor.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T21:15:36.868910+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10381,"accession_number":"0001193125-26-279776","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This Item 8.01 discloses a material acquisition event: Catalyst Pharmaceuticals entered into a Merger Agreement with Angelini Pharma on May 6, 2026, providing for the merger of Angelini's subsidiary with Catalyst, with Catalyst surviving as a wholly-owned subsidiary of Angelini Pharma. The filing updates that the FTC granted early termination of the HSR Act waiting period on June 16, 2026, and the parties expect closing in Q3 2026 subject to customary conditions including stockholder approval. This is a change-of-control transaction material to any reasonable investor.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T21:15:36.868910+00:00","company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","filing_date":"2026-06-23"}]}